Merck KGaA (FRA:MRK) has been given a €103.00 ($119.77) price objective by research analysts at Independent Research GmbH in a research report issued on Thursday. The firm currently has a “neutral” rating on the healthcare company’s stock. Independent Research GmbH’s price objective points to a potential upside of 11.28% from the stock’s previous close.

Several other research firms have also recently weighed in on MRK. Kepler Capital Markets set a €115.00 ($133.72) price objective on Merck KGaA and gave the stock a “buy” rating in a research report on Monday. Warburg Research set a €115.00 ($133.72) price objective on Merck KGaA and gave the stock a “buy” rating in a research report on Thursday. Berenberg Bank set a €116.00 ($134.88) price objective on Merck KGaA and gave the stock a “buy” rating in a research report on Thursday. Commerzbank Ag set a €103.00 ($119.77) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday. Finally, J P Morgan Chase & Co set a €100.00 ($116.28) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday. Thirteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of €109.09 ($126.85).

Shares of Merck KGaA (FRA MRK) opened at €92.56 ($107.63) on Thursday. Merck KGaA has a fifty-two week low of €89.00 ($103.49) and a fifty-two week high of €115.00 ($133.72).

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/merck-kgaa-mrk-pt-set-at-103-00-by-independent-research-gmbh/1689807.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.